jnj-20201103
0000200406false00002004062020-11-032020-11-030000200406us-gaap:CommonStockMember2020-11-032020-11-030000200406jnj:A0.250NotesDue2022Member2020-11-032020-11-030000200406jnj:A0.650NotesDue2024Member2020-11-032020-11-030000200406jnj:A5.50NotesDue2024Member2020-11-032020-11-030000200406jnj:A1.150NotesDue2028Member2020-11-032020-11-030000200406jnj:A1.650NotesDue2035Member2020-11-032020-11-03


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): 
November 3, 2020
Johnson & Johnson
 (Exact name of registrant as specified in its charter)
  
New Jersey1-321522-1024240
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b)) 
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, Par Value $1.00JNJNew York Stock Exchange
0.250% Notes Due January 2022JNJ22New York Stock Exchange
0.650% Notes Due May 2024JNJ24New York Stock Exchange
5.50% Notes Due November 2024JNJ24BPNew York Stock Exchange
1.150% Notes Due November 2028JNJ28New York Stock Exchange
1.650% Notes Due May 2035JNJ35New York Stock Exchange
 
 




 
Item 8.01 Other Events
    
As previously disclosed in Johnson & Johnson’s (the “Company”) most recent Form 10-Q, filed with the Securities and Exchange Commission on October 23, 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion, reducing the award to $2.1 billion regarding certain talc cases (the “Ingham verdict”). At that time, the Company filed an application for a transfer of the case to the Missouri Supreme Court. On November 3, 2020 the Missouri Supreme Court announced its decision not to hear the Company’s appeal of the Ingham verdict. As a result, the Company will record a reserve of approximately $2.1 billion, (excluding interest) consistent with the Ingham verdict, which will be reflected in its 2020 fiscal year-end results. The Company will continue to challenge the Ingham verdict by petitioning the United States Supreme Court for review.               




 
 
 


 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 Johnson & Johnson 
   (Registrant)
 
 
 
 
Date: November 3, 2020By:/s/ Matthew Orlando 
  Matthew Orlando
Corporate Secretary